1.
The production, selling or use of fake or inferior medicines is strictly prohibited.
严禁生产、经营、使用假药或者劣药。
2.
Sample Interpretation of Definition of Adulterated Drugand Misbranded Drug in Drug Management Law
浅析我国《药品管理法》对假劣药的界定
3.
"Furthermore, incidents of counterfeit and low-quality drugs occur from time to time."
此外,社会上假劣药品事件时有发生。
4.
Analysis of Current Status of Counterfeit and Substandard Drugs in China and Exploration on Its Administration Measures;
我国假劣药现状分析及管理对策探讨
5.
The inferior medicines referred to in this article mean those inferior pharmaceutical products that fall into the category of inferior medicines in accordance with the regulations of the "Law of the PRC Governing the Management of Pharmaceutical Products".
本条所称劣药，是指依照《中华人民共和国药品管理法》的规定属于劣药的药品。
6.
The Handling of Three Kinds of Inferior Drug Making Doing and the Betterment of the System of Drugs being Treated as inferior Drugs;
三种违法制劣行为的处理及按劣药论处制度的完善
7.
On the Characteristics and the Detection Measures of Manufacturing or Selling Fake Drugs Crimes;
论生产销售假冒伪劣药品犯罪特点及侦查措施
8.
Study on Establishing Matching Model of Inferior Drug with NIR Spectroscopy
利用近红外光谱仪建立劣药比对模型的研究
9.
An act of making or selling fake medicine or inferior medicine to be mainly administered to babies or infants;
生产、销售的假药、劣药以婴幼儿为主要使用对象的；
10.
The Analysis of the administration system of the counterfeit drug sales in medical institution in China.;
基层医疗机构假药劣药销售监管制度的法律剖析
11.
Furthermore, the incidents of counterfeit and low quality drugs occur from time to time, and there is an urgent need to strengthen the drug monitoring and intensify legislation and its implementation.
此外，社会上假劣药品事件时有发生，迫切需要加强药品监管，加大执法力度。
12.
Medical organization cant bear the great trust of living;
医疗机构不能承受的“生命之重”——论医疗机构提供假药劣药的民事责任归责原则
13.
The Status Quo Survey of False and Inferior Species in Three of Chinese Medicinal Materials Markets in Dali
大理地区中药材市场假劣品现状调查
14.
Our soldiers had very little ammunition so they were fighting at a disadvantage.
我军只有很少的弹药，所以战事处于劣势。
15.
3.In the light of internal environmental factors influencing DCMG,advantages and disadvantages has been summarized.
3、对药材集团内部环境，概括总结出优势劣势。
16.
Non-technical Causes of Fakes Existing in Chinese Medicinal Material Markets;
中药材市场存在假劣品的非技术性原因
17.
Clinical Application Research about Non-inferiority/equivalence Cutoff Being Used in the Re-evaluation of Traditional Chinese Medicine
非劣效/等效性界值在中药临床再评价中的应用研究
18.
Sample Size Estimation and Statistical Inference in a Three-arm Non-inferiority Clinical Trial Including a Placebo and an Active Control
安慰剂和阳性药对照的三臂非劣效临床试验的样本含量估计和统计推断